RT Journal Article
SR Electronic
T1 1532 A phase 1/2 study of safety, tolerability, and pharmacokinetics of SNS-101, a pH-sensitive anti-VISTA mAb, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
JF Journal for ImmunoTherapy of Cancer
JO J Immunother Cancer
FD BMJ Publishing Group Ltd
SP A1755
OP A1755
DO 10.1136/jitc-2023-SITC2023.1532
VO 11
IS Suppl 2
A1 Sen, Shiraj
A1 Call, Justin
A1 Papadopoulos, Kyriakos
A1 Smith, FD
A1 Horst, Edward H van der
YR 2023
UL http://jitc.bmj.com/content/11/Suppl_2/A1755.abstract
AB Markup server — Error Not Found The page you were trying to reach could not be found. Please check the address for the page you were trying to reach. If you believe you have reached this page in error, you may contact us with any questions.